Publication in PNAS unveils molecular pathway required for influenza virus replication with large potential as an antiviral drug target

LightOx May 2020

Xenikos receives FDA Fast Track designation for T-Guard(R) for treating steroid-refractory acute graft-versus-host disease

Xenikos announces IND clearance by the FDA for a pivotal Phase 3 trial using T-Guard® for treating steroid-refractory acute GVHD

Xenikos partners with the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) to conduct a U.S.-based Phase 3 trial to test T-Guard(R) in acute graft-versus-host disease

Xenikos announces data from phase I/II trial with T-Guard™ for treatment of steroid-resistant acute GVHD presented at ASH Annual Meeting